3 Calif stem cell grants revoked

California's stem cell funding agency giveth and it taketh away: Just last week, the agency awarded more than $250 million to stem cell researchers -- the largest research grant round in its five-year history -- but it also terminated three grants awarded in a previous round due to slow progress earlier this year. Human embryonic stem cellsImage: Wikimedia commons, Nissim BenvenistyThe California Institute of Regenerative Medicine (CIRM) identified the underperforming projects by reviewing gr

Written byJef Akst

| 2 min read

Save for Later

Human embryonic stem cells
Image: Wikimedia commons,
Nissim Benvenisty

The California Institute of Regenerative Medicine (CIRM) identified the underperforming projects by reviewing grantees' first year progress reports. These are required by all CIRM grantees in a progress monitoring system that appears to be more rigorous than that of the National Institutes of Health. "The scientific staff are in frequent contact with our CIRM-supported PIs, assessing their progress towards the goals they were approved to pursue," CIRM director Floyd Bloom linkurl:told the California Stem Cell Report;http://californiastemcellreport.blogspot.com/2009/11/cscr-withholds-names-of-terminated.html (CSCR). "Lack of progress can be sufficient grounds to terminate the funding." In February 2007, CIRM's governing board dished out 74 Scientific Excellence through Exploration and Development (SEED) grants totaling more than $46 million. The two-year SEED grants were considered high risk, high reward and designed to bring cellular and developmental biologists who had never worked with human embryonic stem cells into the field. Though most projects were going fine, reviewers identified some programs that were not advancing, Marie Csete, former chief scientific officer of CIRM, said in a presentation at a CIRM meeting last June. The reviewers contacted the PIs, often requesting more data to more accurately assess the situation. "We were interested in hearing what people would normally not send in as a progress report: difficulty getting cell lines grown, difficulty doing certain kinds of experiments," Csete said. Problematic projects got a second look, but if a follow-up progress report still showed little or no advancement and no plan could be created to get it back on track, CIRM could terminate the funding. "Termination is a last option," CIRM's chief communications officer Don Gibbons wrote in an email to The Scientist. "We first work with grantees who are not progressing to get them back on track." One of the three researchers whose grant was revoked linkurl:told CSCR;http://californiastemcellreport.blogspot.com/2009/11/cirm-scrutinizes-grantee-performance.html that he was "bitter" about the decision and emphasized the difference from NIH policy, which allows "the liberty to take the research where it leads you." Another researcher claimed that the action was premature, while the third simply said that he parted "amicably" with CIRM. All three said that they support CIRM and its goals. "This kind of nurturing, interactive relationship with the PIs is absolutely unique in the grant world," Bloom said at the meeting in June. "It's highly commendable, and it's going to make the difference between success or failure, particularly for these intermediate level of successful early experiments where they have to be encouraged to go on and push."
**__Related stories:__***linkurl:CIRM grants delayed;http://www.the-scientist.com/blog/display/55393/
[2nd February 2009]*linkurl:Calif. stem cell agency back on track?;http://www.the-scientist.com/news/home/53676/
[4th October 2007]*linkurl:Calif. stem cell grant raises concerns;http://www.the-scientist.com/news/home/52994/
[26th March 2007]

Meet the Author

Jef Akst

Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

View Full Profile

3 Calif stem cell grants revoked

The Scientist ARCHIVES

Become a Member of

Meet the Author

Jef Akst

Related Research Resources

What Is the Amniotic Fluid Composed of?

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Advancing Drug Discovery with Complex Human In Vitro Models

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Skip the Wait for Protein Stability Data with Aunty

Products

Product News

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform